The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Structural and Functional Basis of Cyclooxygenase Inhibition
Open accessAbstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTStructural and Functional Basis of Cyclooxygenase InhibitionAnna L. Blobaum and Lawrence J. MarnettView Author Information A. B. Hancock Jr. Memorial Laboratory for Cancer Research, Departments of Biochemistry, Chemistry, and Pharmacology, Vanderbilt Institute for Chemical Biology and Center in Molecular Toxicology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 Cite this: J. Med. Chem. 2007, 50, 7, 1425–1441Publication Date (Web):March 7, 2007Publication History Received13 November 2006Published online7 March 2007Published inissue 1 April 2007https://pubs.acs.org/doi/10.1021/jm0613166https://doi.org/10.1021/jm0613166review-articleACS PublicationsCopyright © 2007 American Chemical SocietyRequest reuse permissions This publication is Open Access under the license indicated. Learn MoreArticle Views36826Altmetric-Citations383LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail PDF (1 MB) Get e-AlertscloseSUBJECTS:Crystal structure,Inhibition,Inhibitors,Lipids,Peptides and proteins Get e-Alerts
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Cyclooxygenases: Structural, cellular, and molecular biology
Smith, W. L., DeWitt, D. L., & Garavito, R. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.145 · Cited by 2,925
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
Kurumbail, R. G., Stevens, A. M., Gierse, J. K., McDonald, J. J., Stegeman, R. A., Pak, J. Y., Gildehaus, D., iyashiro, J. M., Penning, T. D., Seibert, K., et al. (1996) · Nature · doi:10.1038/384644a0 · Cited by 1,917
Kujubu, D. A., Fletcher, B. S., Varnum, B. C., Lim, R. W., & Herschman, H. R. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98774-0 · Cited by 1,789
Xie, W. L., Chipman, J. G., Robertson, D. L., Erikson, R. L., & Simmons, D. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.7.2692 · Cited by 1,707
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
Aspirin Selectively Inhibits Prostaglandin Production in Human Platelets
SMITH, J. B., & WILLIS, A. L. (1971) · Nature New Biology · doi:10.1038/newbio231235a0 · Cited by 1,521
Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006) · BMJ · doi:10.1136/bmj.332.7553.1302 · Cited by 1,445
Thun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
Masferrer, J. L., Zweifel, B. S., Manning, P. T., Hauser, S. D., Leahy, K. M., Smith, W. G., Isakson, P. C., & Seibert, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3228 · Cited by 1,310
McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1
Picot, D., Loll, P. J., & Garavito, R. M. (1994) · Nature · doi:10.1038/367243a0 · Cited by 1,265
Meade, E. A., Smith, W. L., & DeWitt, D. L. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53294-4 · Cited by 1,256
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2
Gupta, R. A., & DuBois, R. N. (2001) · Nature Reviews Cancer · doi:10.1038/35094017 · Cited by 1,066
Celecoxib for the Prevention of Sporadic Colorectal Adenomas
Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M., Solomon, S. D., Kim, K., Tang, J., Rosenstein, R. B., Wittes, J., Corle, D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061355 · Cited by 1,048
Grosser, T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27291 · Cited by 1,027
Acetylation of prostaglandin synthase by aspirin.
Roth, G. J., Stanford, N., & Majerus, P. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.8.3073 · Cited by 1,009
Celecoxib for the Prevention of Colorectal Adenomatous Polyps
Arber, N., Eagle, C. J., Spicak, J., Rácz, I., Dite, P., Hajer, J., Zavoral, M., Lechuga, M. J., Gerletti, P., Tang, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061652 · Cited by 975
Indomethacin and Aspirin abolish Prostaglandin Release from the Spleen
FERREIRA, S. H., MONCADA, S., & VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231237a0 · Cited by 941
Moncada, S., Higgs, E. A., & Vane, J. R. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91655-5 · Cited by 882
Topper, J. N., Cai, J., Falb, D., & Gimbrone, M. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.19.10417 · Cited by 843
Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes.
Miyamoto, T., Ogino, N., Yamamoto, S., & Hayaishi, O. (1976) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)33534-2 · Cited by 663
Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2
Luong, C., Miller, A., Barnett, J., Chow, J., Ramesha, C., & Browner, M. F. (1996) · Nature Structural Biology · doi:10.1038/nsb1196-927 · Cited by 618
Different Intracellular Locations for Prostaglandin Endoperoxide H Synthase-1 and −2
Morita, I., Schindler, M., Regier, M. K., Otto, J. C., Hori, T., DeWitt, D. L., & Smith, W. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.18.10902 · Cited by 572
Hippisley-Cox, J., & Coupland, C. (2005) · BMJ · doi:10.1136/bmj.330.7504.1366 · Cited by 561
Dose-Related Kinetics of Aspirin: Presystemic Acetylation of Platelet Cyclooxygenase
Pedersen, A. K., & FitzGerald, G. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411083111902 · Cited by 558
Arachidonic Acid Oxygenation by COX-1 and COX-2
Marnett, L. J., Rowlinson, S. W., Goodwin, D. C., Kalgutkar, A. S., & Lanzo, C. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.22903 · Cited by 523
Self-citationCyclo-oxygenase 2: a pharmacological target for the prevention of cancer
Dannenberg, A. J., Altorki, N. K., Boyle, J. O., Dang, C., Howe, L. R., Weksler, B. B., & Subbaramaiah, K. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00488-0 · Cited by 508
Loll, P. J., Picot, D., & Garavito, R. M. (1995) · Nature Structural Biology · doi:10.1038/nsb0895-637 · Cited by 490
Mechanism of Action of Anti-Inflammatory Drugs
Vane, J. R., & Botting, R. M. (1996) · Scandinavian Journal of Rheumatology · doi:10.3109/03009749609097226 · Cited by 465
The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases.
DeWitt, D. L., el-Harith, E. A., Kraemer, S. A., Andrews, M. J., Yao, E. F., Armstrong, R. L., & Smith, W. L. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)34105-5 · Cited by 429
Gierse, J. K., McDonald, J. J., Hauser, S. D., Rangwala, S. H., Koboldt, C. M., & Seibert, K. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.26.15810 · Cited by 410
Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase.
Copeland, R. A., Williams, J. M., Giannaras, J., Nurnberg, S., Covington, M., Pinto, D., Pick, S., & Trzaskos, J. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11202 · Cited by 408
Ott, E., Nussmeier, N. A., Duke, P. C., Feneck, R. O., Alston, R. P., Snabes, M. C., Hubbard, R. C., Hsu, P. H., Saidman, L. J., & Mangano, D. T. (2003) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(03)00125-9 · Cited by 403
Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin.
Lecomte, M., Laneuville, O., Ji, C., DeWitt, D. L., & Smith, W. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36820-5 · Cited by 371
Leese, P. T., Hubbard, R. C., Karim, A., Isakson, P. C., Yu, S. S., & Geis, G. S. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/00912700022008766 · Cited by 371
A Novel Mechanism of Cyclooxygenase-2 Inhibition Involving Interactions with Ser-530 and Tyr-385
Rowlinson, S. W., Kiefer, J. R., Prusakiewicz, J. J., Pawlitz, J. L., Kozak, K. R., Kalgutkar, A. S., Stallings, W. C., Kurumbail, R. G., & Marnett, L. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305481200 · Cited by 353
Self-citationKalgutkar, A. S., Marnett, A. B., Crews, B. C., Remmel, R. P., & Marnett, L. J. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000004e · Cited by 316
Self-citationThe Productive Conformation of Arachidonic Acid Bound to Prostaglandin Synthase
Malkowski, M. G., Ginell, S. L., Smith, W. L., & Garavito, R. M. (2000) · Science · doi:10.1126/science.289.5486.1933 · Cited by 308
Selinsky, B. S., Gupta, K., Sharkey, C. T., & Loll, P. J. (2001) · Biochemistry · doi:10.1021/bi010045s · Cited by 292
Rome, L. H., & Lands, W. E. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.12.4863 · Cited by 290
Kinetic basis for selective inhibition of cyclo-oxygenases
Gierse, J. K., Koboldt, C. M., Walker, M. C., Seibert, K., & Isakson, P. C. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3390607 · Cited by 287
Oxygenation of Unsaturated Fatty Acids by the Vesicular Gland of Sheep
Hamberg, M., & Samuelsson, B. (1967) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99434-2 · Cited by 282
Stimulation and Blockade of Prostaglandin Biosynthesis
Smith, W. L., & Lands, W. E. M. (1971) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)34171-7 · Cited by 281
Structural insights into the stereochemistry of the cyclooxygenase reaction
Kiefer, J. R., Pawlitz, J. L., Moreland, K. T., Stegeman, R. A., Hood, W. F., Gierse, J. K., Stevens, A. M., Goodwin, D. C., Rowlinson, S. W., Marnett, L. J., et al. (2000) · Nature · doi:10.1038/35011103 · Cited by 278
Self-citationCox-2-Selective Inhibitors: The New Super Aspirins
DeWitt, D. L. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23023-6 · Cited by 261
DIETZ, R., NASTAINCZYK, W., & RUF, H. H. (1988) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1988.tb13793.x · Cited by 256
128th National Meeting American Chemical Society
(1955) · Chemical & Engineering News Archive · doi:10.1021/cen-v033n032.p3286 · Cited by 253
Kalgutkar, A. S., Crews, B. C., Rowlinson, S. W., Marnett, A. B., Kozak, K. R., Remmel, R. P., & Marnett, L. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.925 · Cited by 252
Self-citationCapone, M. L., Tacconelli, S., Sciulli, M. G., Grana, M., Ricciotti, E., Minuz, P., Di Gregorio, P., Merciaro, G., Patrono, C., & Patrignani, P. (2004) · Circulation · doi:10.1161/01.cir.0000124715.27937.78 · Cited by 229
Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population
García Rodríguez, L. A., Varas-Lorenzo, C., Maguire, A., & González-Pérez, A. (2004) · Circulation · doi:10.1161/01.cir.0000132491.96623.04 · Cited by 221
Cyclooxygenase 2 inhibitors: discovery, selectivity and the future
Marnett, L. J., & Kalgutkar, A. S. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01385-1 · Cited by 205
Self-citationProstaglandin Endoperoxide H Synthase-1
Thuresson, E. D., Lakkides, K. M., Rieke, C. J., Sun, Y., Wingerd, B. A., Micielli, R., Mulichak, A. M., Malkowski, M. G., Garavito, R. M., & Smith, W. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009377200 · Cited by 195
Kulmacz, R. J., & Lands, W. E. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38909-3 · Cited by 188
Holtzman, M. J., TURK, J. W., & Shornick, L. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36629-3 · Cited by 188
5 Selective Inhibitors of Cyclooxygenase-2 (COT-2)
Talley, J. J. (1999) · Progress in Medicinal Chemistry · doi:10.1016/s0079-6468(08)70048-1 · Cited by 178
Acetylation of Prostaglandin Endoperoxide Synthetase with Acetylsalicylic Acid
OUDERAA, F. J., BUYTENHEK, M., NUGTEREN, D. H., & VAN DORP, D. A. (1980) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1980.tb04760.x · Cited by 160
Acetylation of the NH2-terminal serine of prostaglandin synthetase by aspirin.
Roth, G. J., & Siok, C. J. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34756-7 · Cited by 147
Mancini, J. A., Riendeau, D., Falgueyret, J., Vickers, P. J., & O’Neill, G. P. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.49.29372 · Cited by 141
Ouellet, M., Riendeau, D., & Percival, M. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251543298 · Cited by 139
Marked Interindividual Variability in the Response to Selective Inhibitors of Cyclooxygenase-2
Fries, S., Großer, T., Price, T. S., Lawson, J. A., Kapoor, S. C., DeMarco, S., Pletcher, M. T., Wiltshire, T., & FitzGerald, G. A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.002 · Cited by 138
The Structure of Mammalian Cyclooxygenases
Garavito, R. M., & Mulichak, A. M. (2003) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.32.110601.141906 · Cited by 137
Wong, E., Bayly, C. I., Waterman, H. L., Riendeau, D., & Mancini, J. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.14.9280 · Cited by 131
Partnering between monomers of cyclooxygenase-2 homodimers
Yuan, C., Rieke, C. J., Rimon, G., Wingerd, B. A., & Smith, W. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601805103 · Cited by 129
Rowlinson, S. W., Crews, B. C., Lanzo, C. A., & Marnett, L. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23305 · Cited by 128
Self-citationSelective COX-2 Inhibitors and Risk of Myocardial Infarction
Krötz, F., Schiele, T. M., Klauß, V., & Sohn, H. (2005) · Journal of Vascular Research · doi:10.1159/000086459 · Cited by 128
Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase‐2
Esser, R. E., Berry, C., Du, Z., Dawson, J., Fox, A., Fujimoto, R. A., Haston, W. O., Kimble, E. F., Koehler, J., Peppard, J., et al. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706078 · Cited by 125
Roth, G. J., Machuga, E. T., & Ozols, J. (1983) · Biochemistry · doi:10.1021/bi00289a010 · Cited by 125
Smith, W. L., Eling, T. E., Kulmacz, R. J., Marnett, L. J., & Tsai, A.-L. (1992) · Biochemistry · doi:10.1021/bi00116a001 · Cited by 122
Self-citationXiao, G., Tsai, A.-L., Palmer, G., Boyar, W. C., Marshall, P. J., & Kulmacz, R. J. (1997) · Biochemistry · doi:10.1021/bi962476u · Cited by 121
Guo, Q., Wang, L., Ruan, K., & Kulmacz, R. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.32.19134 · Cited by 114
Oxyanion Hole Interactions in Serine and Cysteine Proteases
Menard, R., & Storer, A. C. (1992) · Biological Chemistry Hoppe-Seyler · doi:10.1515/bchm3.1992.373.2.393 · Cited by 114
Structural characteristics of prostaglandin synthetase from sheep vesicular gland.
Roth, G. J., Siok, C. J., & Ozols, J. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)86029-5 · Cited by 102
Risks and Benefits of Celecoxib to Prevent Recurrent Adenomas
Psaty, B. M., & Potter, J. D. (2006) · New England Journal of Medicine · doi:10.1056/nejme068158 · Cited by 95
Depré, M., Ehrich, E. W., Hecken, A. V., Lepeleire, I. D., Dallob, A., Wong, P., Porras, A. G., Gertz, B. J., & Schepper, P. J. D. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050736 · Cited by 91
Rowlinson, S. W., Crews, B. C., Goodwin, D. C., Schneider, C. G., Gierse, J. K., & Marnett, L. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.9.6586 · Cited by 87
Self-citationGreig, G. M., Francis, D. A., Falgueyret, J., Ouellet, M., Percival, M. D., Roy, P. J., Bayly, C. I., Mancini, J. A., & O’Neill, G. P. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.5.829 · Cited by 87
Indolyl esters and amides related to indomethacin are selective COX-2 inhibitors
Kalgutkar, A. S. S., Crews, B. C., Saleh, S., Prudhomme, D. R., & Marnett, L. J. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.07.073 · Cited by 85
Self-citationChen, W., Pawelek, T. R., & Kulmacz, R. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.29.20301 · Cited by 82
Rodríguez, L. A. G., & González‐Pérez, A. (2005) · BMC Medicine · doi:10.1186/1741-7015-3-17 · Cited by 76
Greenberg, H. E., Gottesdiener, K. M., Huntington, M. F., Wong, P., Larson, P., Wildonger, L., Gillen, L. P., Dorval, E. P., & Waldman, S. A. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004001224 · Cited by 69
Molecular Basis of the Time-Dependent Inhibition of Cyclooxygenases by Indomethacin
Prusakiewicz, J. J., Felts, A. S., Mackenzie, B. S., & Marnett, L. J. (2004) · Biochemistry · doi:10.1021/bi048534q · Cited by 62
Self-citationCellular regulation of prostaglandin H synthase catalysis
Kulmacz, R. J. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00657-7 · Cited by 56
Therapeutic roles of selective COX-2 inhibitors
Graham, D. Y. (2002) · Gastroenterology · doi:10.1016/s0016-5085(02)80092-0 · Cited by 54
Tsai, A., Wu, G., Palmer, G., Bambai, B., Koehn, J. A., Marshall, P. J., & Kulmacz, R. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21695 · Cited by 53
Comparison of Structural Stabilities of Prostaglandin H Synthase-1 and -2
Xiao, G., Chen, W., & Kulmacz, R. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.12.6801 · Cited by 51
Lanzo, C. A., Sutin, J. D. B., Rowlinson, S. W., et al. (2000) · Biochemistry · doi:10.1021/bi992761o · Cited by 48
Erratum: A transcriptional partner for MAD proteins in TGF-β signalling
Chen, X., Rubock, M. J., & Whitman, M. (1996) · Nature · doi:10.1038/384648b0 · Cited by 48
Mancini, J. A., Vickers, P. J., O’Neill, G. P., Boily, C., Falgueyret, J., & Riendeau, D. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.1.52 · Cited by 47
Tyrosyl radicals in prostaglandin H synthase-1 and -2
Tsai, A.-L., & Kulmacz, R. J. (2000) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(00)00083-6 · Cited by 46
Aldington, S., Shirtcliffe, P., Weatherall, M., & Beasley, R. W. (2005) · PubMed · Cited by 41
Aronoff, D. M., Boutaud, O. G., Marnett, L. J., & Oates, J. A. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.042853 · Cited by 39
Self-citationInhibitor-Induced Changes in the Intrinsic Fluorescence of Human Cyclooxygenase-2
Houtzager, V. M., Ouellet, M., Falgueyret, J., Passmore, L. A., Bayly, C. I., & Percival, M. D. (1996) · Biochemistry · doi:10.1021/bi960053m · Cited by 36
Aldington, S., Shirtcliffe, P., Weatherall, M. W., et al. (2005) · PubMed · Cited by 35
Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors
Anning, P. B., Coles, B., Morton, J., Wang, H., Uddin, J., Morrow, J. D., Dey, S. K., Marnett, L. J., & O’Donnell, V. B. (2006) · Blood · doi:10.1182/blood-2006-02-005330 · Cited by 31
Self-citationAntiplatelet Effects of MK‐852, a Platelet Fibrinogen Receptor Antagonist, in Healthy Volunteers
Greenberg, H. E., Wissel, P. S., Barrett, J., Barchowsky, A., Gould, R. J., Farrell, D., Panebianco, D. L., Hand, E. L., Gillen, L. P., Goldberg, M. R., et al. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/00912700022009116 · Cited by 27
Heme prosthetic group required for acetylation of prostaglandin H synthase by aspirin
Chen, Y. P., & Marnett, L. J. (1989) · The FASEB Journal · doi:10.1096/fasebj.3.11.2506093 · Cited by 26
Self-citationRosenstock, M., Danon, A., & Rimon, G. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(99)00105-5 · Cited by 24
Enantiospecific, selective cyclooxygenase-2 inhibitors
Kozak, K. R., Prusakiewicz, J. J., Rowlinson, S. W., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00133-6 · Cited by 24
Rosenstock, M., Danon, A., Rubin, M., & Rimon, G. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00931-6 · Cited by 21
Structural diversity of selective COX-2 inhibitors
Marnett, L. J., & Kalgutkar, A. S. S. (2004) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7879-1_2 · Cited by 10
Self-citation
Cited by
In situ click chemistry generation of cyclooxygenase-2 inhibitors
Bhardwaj, A., Kaur, J., Wuest, M., & Wuest, F. (2017) · Nature Communications · doi:10.1038/s41467-016-0009-6 · Cited by 7,448
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective
Bindu, S., Mazumder, S., & Bandyopadhyay, U. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114147 · Cited by 1,920
Cyclooxygenases: structural and functional insights
Rouzer, C. A., & Marnett, L. J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800042-jlr200 · Cited by 688
Self-citationRoles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic Approaches
Park, M., & Hong, J. (2016) · Cells · doi:10.3390/cells5020015 · Cited by 627
Li, J., Kuang, Y., Gao, Y., Du, X., Shi, J., & Xu, B. (2013) · Journal of the American Chemical Society · doi:10.1021/ja310019x · Cited by 283
Metadata
- Authors
- Blobaum, A. L., & Marnett, L. J.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2007-03-07
- Volume
- 50
- Issue
- 7
- Pages
- 1425-1441
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1980990431
- Cited by
- 550
- References
- 106
- FWCI
- 10.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.